Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

55 results about "Giant cell" patented technology

A giant cell (multinucleated giant cell, multinucleate giant cell) is a mass formed by the union of several distinct cells (usually histiocytes), often forming a granuloma. It can arise in response to an infection, such as from tuberculosis, herpes, or HIV, or foreign body. These multinucleate giant cells (MGCs) are cells of monocyte or macrophage lineage fused together.

Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.
Owner:IMMUNOMEDICS INC

Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.
Owner:IMMUNOMEDICS INC

Microfluidic device for detection of five indicators of sound child rearing

The present invention discloses a microfluidic device for detection of five indicators of sound child rearing, the microfluidic device includes a microfluidic chip, a temperature control module, a micro motor moving module and a CCD detection module, through the mutual matching of the micro motor moving module, the temperature control module and the microfluidic chip, the processes of capture of target cell specific antigens and cleaning of cell antigens non-specifically adsorbed on microsphere surface by use of antibodies coating the microsphere surface, capture of enzyme labelled antibodies by use of the target cell antigens non-specifically adsorbed on the microsphere surface and catalytic chemiluminiscence of an excitation liquid by use of enzymes non-specifically adsorbed on the microsphere surface and the like can be respectively completed, the CCD detection module is cooperated for acquisition and detection of chemicalluminescence signals on the microsphere surface so as to achieve integration operation of the capture and detection process of five indicator antigens of sound child rearing in serum samples; the five indicators of sound child rearing comprise TOX (Toxoplasma gondii), RUB (Rubella), CMV (cytomegalovirus), HSV-1 (herpe-1), and HSV-2 (herpe-2).
Owner:BEIJING UNIV OF CHEM TECH +1

Methods and Means for Diagnosing Vasculitis

The present inventions relates generally to methods for diagnosing the presence or the risk of development or the therapy control of vasculitis, in particular, of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR) and Takayasu's arteritis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. The presence of antibodies against ferritin or immunoreactive peptides thereof is indicative for the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis. In particular, detection of the presence of antibodies against ferritin or immunoreactive peptides thereof, allows early diagnosis of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis.
Owner:MEDIZINISCHE HOCHSCHULE HANNOVER

Low-macrophage-adhesion/activation culture devices and methods thereof for continuous hematopoiesis and expansion of hematopoietic stem cells

Hematopoietic stem cells are extremely difficult to maintain or expand in vitro. Two observations in traditional long-term bone marrow cultures strongly suggest that macrophages may be at the root of the problem: First, micromolar concentrations of hydrocortisone improve the longevity of long-term bone marrow cultures and hydrocortisone is known as a potent inhibitor of macrophage production of pro-inflammatory cytokines, chemokines, enzymes, nitrogen oxide and reactive oxygen species and redirects macrophages to the anti-inflammatory differentiation pathway; Second, the decline of hematopoiesis in long-term bone marrow cultures coincides with the development of large numbers of adherent and non-adherent macrophages including foreign body giant cells. These adherent macrophages and foreign body giant cells exhibit well-spread morphology, contain numerous lysosomes and phagolysosomes in the cytoplasm and are metabolically active. We hypothesize that hydrocortisone fails to suppress all aspects of macrophage pro-inflammatory activation/differentiation, resulting in the production of inhibitors or toxins of hematopoiesis. Macrophage adhesion in cell culture depends on serum proteins pre-adsorbed to the tissue-culture-treated polystyrene (TC-PS), which adsorbs proteins via mostly hydrophilic interactions. TC-PS is used in almost all tissue culture devices currently available. Cellular adhesion provides a strong stimulus for metabolic, mitotic and certain gene activities. Therefore, we seek to reduce macrophage adhesion and activation by culturing bone marrow cells in tissue culture devices composed of or covered with polymers with very different protein-binding characteristics than TC-PS such as polyethylene (PE) and other polyolefins, the latter bind proteins via exclusively hydrophobic interactions. As a result, polyolefins bind different proteins and in lower quantities than TC-PS. Furthermore, PE does not contain additional chemical features like the phenolic rings of polystyrene that might contribute to protein binding and macrophage adhesion/activation. Using these new culture devices, we developed a drastically different long-term bone marrow culture, the “Low Macrophage-Adhesion/Activation” (LoMAC) bone marrow culture. In LoMAC bone marrow culture, hematopoiesis continues for months to over a year and hematopoietic stem cells are amplified gradually. In stark contrast to traditional long-term bone marrow cultures, de novo erythropoiesis and megakaryocytopoiesis proceed robustly in the LoMAC bone marrow culture and B-lymphocyte and natural killer cell progenitors can be continuously derived. Thus, these new culture devices and the associated LoMAC culture method offer a new way to study hematopoiesis in vitro and provide a more robust platform for the expansion of hematopoietic stem cells and progenitors ex vivo.
Owner:TSAI SCHICKWANN

AIDS immune cell therapy instrument

The invention discloses an AIDS immune cell therapy apparatus, which is applicable to the medicine field. The AIDS immune cell therapy apparatus is characterized in that blood and plasma separators, by which plasma, individual blood cells and multinuclear giant cells which are formed due to HIV boarding, are prepared; by virtue of an exogenous gene transfection technique, a CD4+T cell line, which can bond HIV, is prepared, the CD4+T cell line undergoes amplification and the CD4+T cell line is covered by virtue of a high-biocompatibility material, so that a purifier is prepared; and then, agarose, which is subjected to a gradient concentration, is added, and the CD4+T cell line in the purifier is immobilized so as to take an effect on adsorbing the HIV; the purifier, together with the separators, functions as key parts of an extracorporeal circulation device; when blood passes through the blood separator, the multinuclear giant cells which contain the HIV are filtered out, subsequently, when the plasma, which is separated by virtue of the plasma separator, passes through the purifier, HIV in the plasma is adsorbed and scavenged by virtue of a purifying agent, the purified plasma joins with the individual blood cells which are separated by virtue of the plasma separator, and then the plasma is returned back, so that the purpose of scavenging the HIVs inside and outside the blood cells by virtue of a detoxifying and purifying therapy is achieved.
Owner:运城同创医疗管理有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products